NCT02513485View on ClinicalTrials.gov

Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 9, 2015

Primary Completion Date

February 21, 2020

Study Completion Date

August 1, 2020

Conditions
Depression
Interventions
DRUG

Levodopa+carbidopa

Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.

DRUG

Placebo

A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.

Trial Locations (1)

30322

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER

NCT02513485 - Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa | Biotech Hunter | Biotech Hunter